Novel imaging approaches improve estimation of treatment response in breast cancer, highlighting tumour heterogeneity and biology.
The use of [ 18 F]fluorodeoxyglucose positron emission tomography/computed tomography ([ 18 F]FDG PET/CT) in breast cancer response assessment and monitoring is well established. However, there are limitations not only to the use of [ 18 F]FDG PET/CT in breast cancer, but also deficiencies in the conventional imaging assessment of treatment response. Breast cancer is biologically heterogeneous, and heterogeneity of tumours limits the accuracy of [ 18 F]FDG PET/CT assessment in some subtypes of breast cancer. Increased understanding of tumour biology and the tumour microenvironment have led to the development of new, specific radio-tracers. These targeted tracers may offer a solution in terms of more accurate response assessment, and prognostication.
No takes yet. Share an insight, caveat, or question.
Sharkey et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: